
Overview
Background
Dr Jodi Saunus is a senior fellow who specialises in translational research on metastatic breast cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research in 2022 to help facilitate patient-focused research at the interface of biomedical R&D and clinical practice.
Dr Saunus has an honours degree in biochemistry and biomedical science, a PhD in breast cancer molecular genetics, and broad post-doctoral experience in immunology, molecular cell biology, pathology informatics, and early-phase investigator-initiated clinical trials. Her current portfolio focuses finding new ways to improve the clinical management of aggressive breast cancer, with a focus on triple-negative breast cancer, and the prevention and treatment of brain metastases. This work spans across multiple disciplines and capabilities, and broadly involves:
- Molecular profiling of patient-donated blood and tumour tissue samples to identify features that can predict treatment response, or represent previously uncharacterised therapeutic targets.
- Using experimental models of breast cancer metastasis to learn about the molecular mechanisms exploited by cancer cells to survive and grow in brain tissue.
- Developing innovative treatment strategies that work differently to conventional cancer drugs, including alpha-particle endoradiotherapy and in-situ vaccination.
With an outstanding network of collaborators from academia and clinical practice, she has secured more than $6M to fund this work and has a track record of publishing in prominent biomedical research journals (e.g., Cancer Research, Nature, Science Translational Medicine, Nature Communications and The Journal of Pathology).
Peripherally, Jodi is a strong proponent of biospecimen banking, and clinician and consumer engagement in translational research.
Availability
- Dr Jodi Saunus is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Doctor of Philosophy, The University of Queensland
Research interests
-
Biomarkers of triple-negative breast cancer progression and response to therapy
Using published datasets, and tissue donated by Brisbane breast cancer patients, we're trying to identify new biomarkers of prognosis and treatment response in breast cancer.
-
Understanding how the triple-negative breast cancer transcriptome is rewired during tumour progression
We apply mathematical approaches to analyse transcriptional networks in TNBC, illuminating how cell biology evolves during tumour development and post-treatment relapse.
-
Understanding the brain metastasis immune microenvironment
In collaboration with immuno-oncology experts at the Peter MacCallum Cancer Centre in Melbourne, we are studying the expression of common tumour antigens to develop strategies for vaccination against cancer.
-
Therapeutic antibody uptake in brain metastases
Brain metastases are broadly refractory to existing systemic therapies. We believe that abnormal vascular function and interstitial fluid dynamics in these tumours may contribute more than previously appreciated. We aim to engineer molecular-targeted carriers that improve the effectiveness and reduce the side-effects of radiotherapy and chemotherapy.
Works
Search Professor Jodi Saunus’s works on UQ eSpace
2005
Conference Publication
Hur post-transcriptionally regulates BRCA1: involvement of elements in the BRCA1 3' untranslated region
Saunus, J. M., Wardrop, S. L., French, J. D., Beveridge, D. J., Hatchell, E. C., Gason, A. A., Simpson, K.J., Leedman, P. J. and Brown, M. A. (2005). Hur post-transcriptionally regulates BRCA1: involvement of elements in the BRCA1 3' untranslated region. Molecular Approaches to Controlling Cancer, New York, 3-5 June, 2005.
2005
Conference Publication
Transcriptional and post-transcriptional regulation of the breast cancer susceptibility gene 1 (BRCA1)
Wardrop, S. L., Saunus, J. M., French, J. D., Leedman, P. J. and Brown, M. A. (2005). Transcriptional and post-transcriptional regulation of the breast cancer susceptibility gene 1 (BRCA1). National Cancer Research Institute Conference, Birmingham, UK, 2-5 Oct, 2005.
2005
Conference Publication
Regulation of BRCA1 by Heregulin
French, J. D., Saunus, J. M., Wardrop, S. L. and Brown, M. A. (2005). Regulation of BRCA1 by Heregulin. Familial Cancer 2005: Research and Practice, Couran Cove, 30 Aug - 3 Sept, 2005.
2002
Conference Publication
Identification of cis and trans regulators in the BRCA1 3'untranslated region
Saunus, J. M., Wardrop, S. L. and Brown, M. A. (2002). Identification of cis and trans regulators in the BRCA1 3'untranslated region. ComBio 2002, Sydney, Australia, 29 September - 3 October, 2002. Kent Town, South Australia:
Funding
Current funding
Supervision
Availability
- Dr Jodi Saunus is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Development of new theranostic agents for metastatic breast cancer surveillance and treatment
Most of the time, treatments for early breast cancer successfully prevent metastatic spread, but 10% of Australian patients still develop lethal recurrences within 5 years. Rather than waiting to see which patients develop symptoms of a possible relapse (e.g., headaches, respiratory symptoms), we are getting better at detecting metastasis early. Patients deemed to be at ‘high risk’ are offered regular PET or MRI scans, allowing earlier intervention and better quality-of-life. PET imaging of radioactive tracers is more specific than MRI, but the standard tracer used in oncology – [18F]fluorodeoxyglucose (FDG) – is not useful for imaging the brain. We are seeking a student to help us develop agents that seek out tumour cells more specifically than FDG and can also be engineered to function as therapeutics. The project is flexible depending on the successful candidate’s expertise and interest (e.g., in vivo models of metastatic breast cancer, protein chemistry and/or molecular biology).
Supervision history
Current supervision
-
Doctor Philosophy
Epigenomic determinants of chemotherapy response in triple-negative breast cancer
Principal Advisor
Other advisors: Professor Chris Pyke, Associate Professor Adam Ewing
-
Doctor Philosophy
Epigenomic determinants of chemotherapy response in triple-negative breast cancer
Principal Advisor
Other advisors: Professor Chris Pyke, Associate Professor Adam Ewing
-
Master Philosophy
Treatment patterns and prognostic indicators in triple-negative breast cancer: a multicentre study of contemporary cases from Queensland, Australia
Principal Advisor
Other advisors: Professor Chris Pyke
-
Doctor Philosophy
Investigating the diagnostic and functional significance of specific epigenomic features in triple-negative breast cancer (TNBC)
Principal Advisor
Other advisors: Honorary Professor Kum Kum Khanna
-
Doctor Philosophy
Strategies to improve immunotherapy for patients with glioblastoma or breast cancer brain metastases
Associate Advisor
Other advisors: Professor Fiona Simpson, Professor Nikolas Haass
-
Doctor Philosophy
The effect of avidity on nanobody-based formats for theranostic applications
Associate Advisor
Other advisors: Dr Nick Fletcher, Dr Pie Huda, Professor Kristofer Thurecht
-
Master Philosophy
Development and characterization of bispecific and bivalent nanobodies for targeting ErBb receptors
Associate Advisor
Other advisors: Dr Nick Fletcher, Dr Pie Huda, Professor Kristofer Thurecht
-
Doctor Philosophy
Factors impacting receptor processing in response to peptide and antibody ligands
Associate Advisor
-
Doctor Philosophy
Obesity and triple-negative breast cancer: an epidemiological study
Associate Advisor
Other advisors: Dr Melinda Protani, Dr Louise Marquart-Wilson
-
Doctor Philosophy
Triple-negative breast cancer in Australia: investigating factors associated with prognosis
Associate Advisor
Other advisors: Dr Melinda Protani, Dr Louise Marquart-Wilson
-
Doctor Philosophy
Applying long-read sequencing technologies to cancer genomes
Associate Advisor
Other advisors: Dr Yuanhao Yang, Dr Sandra Richardson, Associate Professor Adam Ewing
Completed supervision
-
2022
Doctor Philosophy
Development of theranostic nanomedicines for breast cancer brain metastases
Principal Advisor
Other advisors: Professor Sunil Lakhani
-
2022
Doctor Philosophy
Investigation of epigenetic influences on DNA methylation in Triple Negative Breast Cancer
Principal Advisor
Other advisors: Professor Melissa Brown, Professor Sunil Lakhani
-
2021
Doctor Philosophy
Detailed Characterisation of Metaplastic Breast Carcinoma
Associate Advisor
Other advisors: Professor Sunil Lakhani, Associate Professor Amy McCart Reed
-
2016
Doctor Philosophy
Identification of new prognostic biomarker for triple negative breast cancer
Associate Advisor
Other advisors: Professor Sunil Lakhani, Associate Professor Peter Simpson
-
2015
Doctor Philosophy
Heregulin/HER3 signalling increases invasive behaviour of HER2-positive breast cancer cells
Associate Advisor
Other advisors: Professor Sunil Lakhani
Media
Enquiries
Contact Dr Jodi Saunus directly for media enquiries about:
- brain metastases
- breast cancer
- metastatic breast cancer
- stage IV breast cancer
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: